

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Brentuximab vedotin for untreated CD30-positive
peripheral T-cell lymphoma (ID1586)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues have been identified by stakeholders during scoping or consultation

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

N/A

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified

Approved by Associate Director (name): Jasdeep Hayre.....

Date: 18/09/2019